Therapeutic angiogenesis by gene transfer in critical limb and myocardial ischemia

Area of Science:

• Cardiovascular Medicine
• Regenerative Medicine
• Gene Therapy

Background:

• Cardiovascular atherosclerotic diseases are a major global health burden, causing significant morbidity and mortality.
• Current medical, surgical, and percutaneous therapies do not benefit all patients, particularly those unsuitable for revascularization.
• Therapeutic angiogenesis aims to develop new blood vessels (endogenous bypass conduits) around blocked arteries.

Purpose of the Study:

• To review gene transfer strategies for therapeutic angiogenesis.
• To focus on promoting collateral blood vessel development in critical limb and myocardial ischemia.
• To discuss the roles of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF).

Main Methods:

• Review of existing research on gene transfer for therapeutic angiogenesis.
• Analysis of studies involving angiogenic growth factors like VEGF and FGF.
• Examination of preclinical and clinical trial data.

Main Results:

• Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) are well-studied angiogenic factors.
• Gene transfer is a key strategy for delivering these factors to promote neovascularization.
• Therapeutic angiogenesis shows potential for creating functional collateral circulation.

Conclusions:

• Gene transfer strategies hold promise for treating critical limb and myocardial ischemia.
• Therapeutic angiogenesis can provide alternative revascularization options for non-ideal surgical candidates.
• Further research and clinical application of VEGF and FGF gene therapies are warranted.